Fetal Growth Restriction a Case Control Study

N/ANot Yet RecruitingNCT07025031

National University of Malaysia58 enrolled

Overview

The study aims to investigate the responsible factors that leads to idiopathic fetal growth restriction.

The study aims to investigate the relationship between maternal serum level of progesterone, immune-expression of HMOX-1 a placental angiogenesis marker with idiopathic fetal growth restriction.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Idiopathic Fetal Growth Restriction

Eligibility

Sex: FEMALEMin age: 19 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * singleton * dated pregnancy Exclusion Criteria: * fetus with structural or chromosomal anomaly * receive treatments such as aspirin, progestogen, low molecular weight heparin * has pre-existing medical disorders such as autoimmune disease, hypertension, diabetes * smoking * suspected intrauterine infection

Locations (1)

Hospital Canselor Tuanku Muhriz

Kuala Lumpur, Kuala Lumpur, Malaysia

Outcomes

Primary Outcomes

Maternal serum level of progesterone

Maternal blood will be withdrawn and serum isolated. Measurement of progesterone level will be performed from the serum sample using ELISA.

Time frame: At the point of recruitment from 24 until 32 weeks gestation.

Placental immunoexpression of Heme Oxygenase 1

Immunoexpression of Heme Oxygenase 1 in syncytiotrophoblasts, cytotrophoblasts, fetal endothelial cells, maternal vessels and decidual cells.

Time frame: At delivery within 24 until 38 weeks gestation.

Secondary Outcomes

Placenta histopathology examination

Placenta will be examined histopathologically

Time frame: At delivery within 24 until 38 weeks gestation

Central Contacts

Rahana Abd Rahman, MOG (UKM)

CONTACT

+60122719985 drrahana@hctm.ukm.edu.my

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.